ePT--the Electronic Newsletter of Pharmaceutical Technology
Vincent L. Vilker, Ph.D., has been appointed director of FDA's Office of Testing and Research (OTR). Vilker was formerly chief of the Biotechnology Division at the National Institute of Standards.
National Institute of Standards and Technology biotechnology chief Vincent L. Vilker, PhD, has been appointed director of FDA's Office of Testing and Research (OTR), according to a July 13 statement from FDA Office of Pharmaceutical Sciences Director Helen Winkle:
It is my pleasure to announce that Vincent L. Vilker, Ph.D., has been appointed as the Director, Office of Testing and Research (OTR), within the Office of Pharmaceutical Science.
Dr. Vilker joins us from the National Institute of Standards where he was Chief of the Biotechnology Division.
Prior to that, he served on the faculty of the Department of Chemical Engineering at the University of California, Los Angeles.
His expertise in chemical engineering and biotechnology make him the ideal person to assume responsibility of this Office.
Dr. Vilker received a B.S. in Chemical Engineering from the University of Wisconsin and a Ph.D. also in Chemical Engineering from the Massachusetts Institute of Technology.
Since its establishment in 1995, OTR has grown into a very viable part of the Center. I think we can all be proud of how the staff has met numerous scientific challenges in enhancing its science base over the past years to support the Center's regulatory policies and decision making processes. I personally appreciate Dr. Vilker's agreeing to accept the position and we all look forward to working closely with him on related research and testing activities in the coming months.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.